PD-L1 expression was evaluable in 35 patients and using 5% or higher cutoff for tumor cell staining, 12/35 (34.3%) were PD-L1+; ORR was 50.0% in PD-L1+ patients vs. 4.3% in PD-L1−patients. This evidence concerns the gene CD274 and neoplasm.